| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_44ccbd6c2728a643c8b164abdb8af8c0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a96c4e3dca0a38de25b0dd75e0edf0aa |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6849
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6883
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6803
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F15-0086
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-282
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-641 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48 |
| filingDate |
2013-01-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_14d87d8f657582013ab534cf9df1129d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1e732f9f969eec71601a6c6caa6a3800
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e05147e97fa1b06e44c979aaef2446ec
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4de68c0a05c825b12e8244ac6eaa1029
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_285da9a9c9d7e125b2d1d85a75d144af |
| publicationDate |
2014-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-2800586-A1 |
| titleOfInvention |
Ligand-targeted molecules and methods thereof |
| abstract |
The present invention relates to ligand-targeted molecules and ligand drug conjugates (LDCs) comprising a ligand connected to a functional group, which is connected to a linker, wich in turn is bonded to a drug. The LDCs of the present invention also comprise platinum coordination complex wherein the platinum is connected to the linker through monocarboxylato and O→Pt coordinate bonds. The present invention also relates to methods for preparing these ligand drug conjugates. The present invention further relates to methods for the treatment of tumours using the ligand drug conjugates of the present invention. |
| priorityDate |
2012-01-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |